Your prescriber may need a to get a PA before a treatment, service or prescription can be covered by your health plan
Fiber-rich, slow-digesting carbs help stabilize blood sugar and reduce fat storage
In September 2022, Eli Lilly published the results of its preclinical studies on LY3437943 in the journal Cell Metabolism, in an article titled "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." In vitro and in vivo validation of the triple agonist effect of LY3437943: Eli Lilly's research results show that LY3437943 demonstrates superior weight loss effects compared to GLP-1 receptor (GLP-1R) selective agonists (GLP-1 RA), GLP-1R and GCGR dual agonists (Cotadutide or 05677), and GLP-1R and GIPR dual agonists
Our healthcare team will collaborate with you to devise a bespoke peptide therapy plan that aligns with your specific needs and objectives
Food Supplement Do not exceed the recommended daily intake
Each pen contains four doses, which is enough for your first 28 days of treatment
